相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Rachael M. Zemek et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival
Saskia J. Santegoets et al.
CLINICAL CANCER RESEARCH (2019)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Genetic and transcriptional evolution alters cancer cell line drug response
Uri Ben-David et al.
NATURE (2018)
The hallmarks of successful anticancer immunotherapy
Lorenzo Galluzzi et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer Therapy
Matthew M. Gubin et al.
CELL (2018)
Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma
Hyun-Sung Lee et al.
JCI INSIGHT (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
W. Joost Lesterhuis et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei et al.
CELL (2017)
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Aleix Prat et al.
CANCER RESEARCH (2017)
Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
Sophie Sneddon et al.
BMC CANCER (2017)
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses
Kelly D. Moynihan et al.
NATURE MEDICINE (2016)
The Best Model of a Cat Is Several Cats
Claes Gustafsson et al.
TRENDS IN BIOTECHNOLOGY (2016)
Sex differences in immune responses
Sabra L. Klein et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Sidi Chen et al.
CELL (2015)
Vital signs monitoring during injectable and inhalant anesthesia in mice
Atsushi Tsukamoto et al.
EXPERIMENTAL ANIMALS (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das et al.
JOURNAL OF IMMUNOLOGY (2015)
Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
Christel Devaud et al.
ONCOIMMUNOLOGY (2013)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Guidelines for the welfare and use of animals in cancer research
P. Workman et al.
BRITISH JOURNAL OF CANCER (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Aging and innate immunity in the mouse: impact of intrinsic and extrinsic factors
Elizabeth J. Kovacs et al.
TRENDS IN IMMUNOLOGY (2009)
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
RPM Sutmuller et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
分享论文
